Reaction
Pseudocirrhosis reporting signals
As of the last recalculation, Pseudocirrhosis appears in 324 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is FULVESTRANT (PRR 202.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fulvestrant | 79 | 202.8 | 203.3 |
| Paclitaxel (Aibumin-Bound) | 129 | 166.8 | 167.1 |
| Anastrozole Tablets | 45 | 156.3 | 156.6 |
| Paclitaxel | 136 | 151.3 | 151.5 |
| Gemcitabine | 68 | 140.1 | 140.3 |
| Gemcitabine Hydrochloride | 76 | 119.9 | 120.1 |
| Exemestane | 33 | 110.1 | 110.3 |
| Anastrozole | 49 | 100.8 | 101.0 |
| Everolimus Tablets | 22 | 90.4 | 90.5 |
| Fam-Trastuzumab Deruxtecan-Nxki | 12 | 79.4 | 79.5 |
| Letrozole Tablets | 46 | 71.4 | 71.5 |
| Abemaciclib | 20 | 68.4 | 68.5 |
| Capecitabine | 73 | 65.9 | 65.9 |
| Letrozole | 47 | 57.2 | 57.2 |
| Pertuzumab | 22 | 55.7 | 55.7 |
| Bevacizumab | 72 | 47.7 | 47.8 |
| Docetaxel Anhydrous | 36 | 38.5 | 38.5 |
| Docetaxel | 36 | 38.5 | 38.5 |
| Palbociclib | 47 | 36.9 | 36.9 |
| Ado-Trastuzumab Emtansine | 4 | 30.8 | 30.9 |
| Oxaliplatin | 29 | 27.5 | 27.5 |
| Panitumumab | 6 | 25.1 | 25.1 |